{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:24:37Z","timestamp":1792243477623,"version":"4.4.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ygyno.2016.01.019","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T07:45:45Z","timestamp":1453535145000},"page":"565-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Genetic testing for hereditary cancer predisposition: BRCA1\/2, Lynch syndrome, and beyond"],"prefix":"10.1016","volume":"140","author":[{"given":"M.J.","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.I.","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mantia-Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.01.019_bb0005","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.6004\/jnccn.2014.0127","article-title":"National comprehensive cancer network","volume":"12","author":"Daly","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/M13-2747","article-title":"Force USPST. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0015","series-title":"Knowledge, Attitudes, and Utilization of BRCA Testing among Obstetricians and Gynecologists: UT Health Science Center at Houston","author":"Nassef","year":"2012"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0020","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0025","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","author":"Breast Cancer Linkage C","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0030","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2010.01.054","article-title":"Hereditary and familial colon cancer","volume":"138","author":"Jasperson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0035","doi-asserted-by":"crossref","first-page":"959","DOI":"10.6004\/jnccn.2015.0116","article-title":"Colorectal cancer screening, version 1.2015","volume":"13","author":"Provenzale","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0040","first-page":"644","article-title":"Carcinoma of the breast and ovary in three families","volume":"133","author":"Lynch","year":"1971","journal-title":"Surg. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0045","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0016-5085(19)34179-4","article-title":"Heredity and adenocarcinoma of the colon","volume":"53","author":"Lynch","year":"1967","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L","article-title":"Cancer risk in mutation carriers of DNA-mismatch-repair genes","volume":"81","author":"Aarnio","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2009.02.001","article-title":"The contribution of BRCA1 and BRCA2 to ovarian cancer","volume":"3","author":"Ramus","year":"2009","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0060","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0065","article-title":"PMS2 monoallelic mutation carriers: the known unknown","author":"Goodenberger","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0070","first-page":"2807","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer Am. Cancer Soc."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-0004.2008.01125.x","article-title":"Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations","volume":"75","author":"Barrow","year":"2009","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0080","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.AOG.0000154885.44002.ae","article-title":"Gynecologic cancer as a \"sentinel cancer\" for women with hereditary nonpolyposis colorectal cancer syndrome","volume":"105","author":"Lu","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0090","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ygyno.2012.01.049","article-title":"Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer\u226470years","volume":"125","author":"Leenen","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0095","first-page":"1384","article-title":"Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz\u2013Jeghers syndrome and four with adenoma malignum of the cervix","volume":"50","author":"Young","year":"1982","journal-title":"Cancer Am. Cancer Soc."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/376435","article-title":"Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America","volume":"73","author":"Toro","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/humu.22559","article-title":"Germline TP53 mutations and the changing landscape of Li\u2013Fraumeni syndrome","volume":"35","author":"Kamihara","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ng.2503","article-title":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","volume":"45","author":"Palles","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0125","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1158\/0008-5472.CAN-06-1114","article-title":"Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients","volume":"66","author":"Hampel","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0130","article-title":"Genetic testing for RAD51C mutations: in the clinic and community","author":"Sopik","year":"2014","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0135","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.40.12.e131","article-title":"Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility","volume":"40","author":"Heikkinen","year":"2003","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0145","doi-asserted-by":"crossref","first-page":"900","DOI":"10.7326\/0003-4819-157-11-201212040-00539","article-title":"Force* USPST. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0150","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0160","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo\u2013oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0170","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0175","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group","volume":"339","author":"Narod","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0180","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"94","author":"Narod","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0185","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group","volume":"25","author":"Brohet","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMoa052627","article-title":"Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome","volume":"354","author":"Schmeler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0195","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(15)00212-0","article-title":"Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27276 women with endometrial cancer from 36 epidemiological studies","volume":"16","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.2015.6789","article-title":"Female hormonal factors and the risk of endometrial cancer in Lynch syndrome","volume":"314","author":"Dashti","year":"2015","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0205","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0210","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2009.24.2057","article-title":"Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast\/ovarian cancer risks","volume":"28","author":"Oktay","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0215","first-page":"1652","article-title":"Comparison of age at natural menopause in BRCA1\/2 mutation carriers with a non-clinic-based sample of women in Northern California","volume":"119","author":"Lin","year":"2013","journal-title":"Cancer Am. Cancer Soc."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0220","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10689-009-9265-5","article-title":"Attitude towards pre-implantation genetic diagnosis for hereditary cancer","volume":"8","author":"Lammens","year":"2009","journal-title":"Familial Cancer"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/GIM.0b013e318163487d","article-title":"Uptake and timing of bilateral prophylactic salpingo\u2013oophorectomy among BRCA1 and BRCA2 mutation carriers","volume":"10","author":"Bradbury","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2006.07.4922","article-title":"Predictors of prophylactic bilateral salpingo\u2013oophorectomy compared with gynecologic screening use in BRCA1\/2 mutation carriers","volume":"25","author":"Madalinska","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0235","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ygyno.2008.11.039","article-title":"A prospective study of quality of life among women undergoing risk-reducing salpingo\u2013oophorectomy versus gynecologic screening for ovarian cancer","volume":"112","author":"Fang","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0240","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo\u2013oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0245","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1200\/JCO.2006.07.2462","article-title":"Validation of a self-administered, computerized tool for collecting and displaying the family history of cancer","volume":"24","author":"Acheson","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Committee","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0255","doi-asserted-by":"crossref","first-page":"833-+","DOI":"10.1200\/JCO.2013.50.9257","article-title":"American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers","volume":"32","author":"Lu","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0260","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1200\/JCO.2008.17.5950","article-title":"Feasibility of screening for Lynch syndrome among patients with colorectal cancer","volume":"26","author":"Hampel","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/GIM.0b013e3181cd666c","article-title":"The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer","volume":"12","author":"Mvundura","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.51.2129","article-title":"Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60years optimizes triage for population-level germline mismatch repair gene mutation testing","volume":"32","author":"Buchanan","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0280","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.6004\/jnccn.2011.0106","article-title":"Interpretation of genetic testing for Lynch syndrome in patients with putative familial colorectal cancer","volume":"9","author":"Rybak","year":"2011","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0285","first-page":"2","article-title":"Cost analysis comparing universal tumor testing to clinically based criteria in the evaluation of endometrial adenocarcinomas for Lynch syndrome","volume":"133","author":"Brueg","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0290","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv005","article-title":"Comparative effectiveness of screening strategies for Lynch syndrome","volume":"107","author":"Barzi","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0295","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/gim.2015.53","article-title":"The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates","volume":"17","author":"Grosse","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0300","doi-asserted-by":"crossref","first-page":"606","DOI":"10.6004\/jnccn.2010.0045","article-title":"Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients\u2014will the ends justify the means?","volume":"8","author":"Hall","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0305","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.2012.45.1674","article-title":"Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing Lynch syndrome in a large academic medical center","volume":"31","author":"Heald","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0310","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.6004\/jnccn.2014.0128","article-title":"Gene panel testing for inherited cancer risk","volume":"12","author":"Hall","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0315","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1126\/science.1088753","article-title":"The BRCT domain is a phospho-protein binding domain","volume":"302","author":"Yu","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.6004\/jnccn.2006.0017","article-title":"Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers","volume":"4","author":"Domchek","year":"2006","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0325","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/jsm.12377","article-title":"The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis","volume":"11","author":"Cui","year":"2014","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0330","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/AOG.0000000000000620","article-title":"Female sexual dysfunction focus on low desire","volume":"125","author":"Kingsberg","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0335","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ygyno.2015.06.020","article-title":"Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo\u2013oophorectomy","volume":"138","author":"Garcia","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0340","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2014.12.031","article-title":"Risk-reducing salpingectomy with delayed oophorectomy in BRCA1\/2 mutation carriers: patients' and professionals' perspectives","volume":"136","author":"Arts-de Jong","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.01.019_bb0345","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/jwh.1999.8.347","article-title":"Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy","volume":"8","author":"Colditz","year":"1999","journal-title":"J. Women's Health"},{"key":"10.1016\/j.ygyno.2016.01.019_bb0350","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/IGC.0b013e3181a83cd5","article-title":"Fatigue and quality of life after risk-reducing salpingo\u2013oophorectomy in women at increased risk for hereditary breast\u2013ovarian cancer","volume":"19","author":"Michelsen","year":"2009","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816300166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816300166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T06:36:34Z","timestamp":1748759794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816300166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0090825816300166"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.01.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic testing for hereditary cancer predisposition: BRCA1\/2, Lynch syndrome, and beyond","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}